Atinvicitinib, a novel, second-generation selective JAK1 inhibitor for the treatment of allergic dermatitis and atopic dermatitis in dogs
The onset of allergic dermatitis in dogs involves a complex immunological cascade which is largely mediated by the JAK-STAT signalling pathway. Several isolated enzyme and cell-based signalling pathway engagement assays were performed in vitro to evaluate the potency and selectivity of atinvicitinib, a novel second-generation JAK inhibitor. Atinvicitinib inhibited JAK1, JAK2, JAK3, and TYK2 activity in isolated human enzyme assays with IC 50 s of 0.43, 5.9, 1130 and 13.02 nM respectively, demonstrating a greater than 10-fold selectivity for JAK1 over the other JAK enzymes. When evaluated against a panel of 265 human kinases, atinvicitinib displayed a greater than 900-fold selectivity for JAK1. Additionally, when tested at a concentration of 10 µM against a panel of 112 rat, guinea pig, or human enzymes, transporters and receptors, atinvicitinib did not demonstrate stimulatory or inhibitory activity. The signalling of IL-6 (JAK1/JAK2) and EPO (JAK2) in human cell-based pathway engagement assays was inhibited by atinvicitinib with IC 50 s of 41.5 and 456 nM, respectively, consistent with the > 10-fold JAK1 selectivity displayed in isolated JAK enzyme assays. The signalling of JAK1 dependent cytokines involved in inflammation and allergy (IL-4 and IL-13) and pruritus (IL-31) in canine DH82 cells was inhibited by atinvicitinib at IC 50 s between 2.9 and 33.6 nM. These results demonstrate that atinvicitinib selectively inhibits JAK1 enzyme activity in human enzyme and cell-based assays in vitro, and that its potency against canine JAK1 in a canine cell-based system is comparable to that in human cells. While additional complementary studies are warranted, these data indicate the potential of atinvicitinib to selectively inhibit pro-inflammatory (IL-2 and IL-6), pro-allergenic (IL-4 and IL-13) and pruritogenic (IL-31) JAK1-dependent cytokines in canine allergic dermatitis.
Authors
- Jonathan Young (ORCID: https://orcid.org/0000-0002-3350-9159)
- Timothy J. Kowalski (ORCID: https://orcid.org/0000-0002-0659-9857)
- Rafael Fernández
- Joep Verdellen
- Youri Post
- Sara Dinverno
- Jason Brubaker
Institutions
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ET International (United States) (US)
Publication Details
- Journal
- BMC Veterinary Research
- Published
- 2026-11-16
- DOI
- https://doi.org/10.1186/s12917-026-06047-w
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00